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Adjuvants: an essential component of neisseria vaccines
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Introduction
Pathogenic Neisseria species are mainly responsible for
meningococcal and gonorrhoeal disease. Approximately 62
million people get infected annually with gonorrhoea, while
N. meningitidis is one of the main killers responsible for
bacterial meningitis, principally in young children, and the
only bacterium capable of generating epidemics taking more
than 30, 000 lives each year (1). In this paper, we will focus
mainly on the impact of adjuvants on N. meningitidis vaccine
formulation.
Current meningococcal vaccines are administered by the
parenteral route and adsorbed onto aluminium salts; early
vaccines used native polysaccharides (Ps) from serogroups
A, C, Y, and W135 but Ps vaccines are poorly immunogenic in
young infants, fail to induce immunological memory and do
not provide protection for more than 3-5 years (1).
Immunogenicity of Ps was greatly improved when chemically
conjugated to a protein carrier, while also inducing long term
memory in adults and young infants. Conjugated vaccines
have been shown to be very effective, but are too expensive
for developing countries, nevertheless adjuvant strategies
are being applied to reduce costs and increase
immunogenicity. Furthermore, the development of vaccines
against serogroup B, accounting for 2000-8000 deaths
annually in developed and developing countries, has been
vastly hindered because its’ Ps is less immunogenic and cross
Adjuvants may be classified into delivery systems and immune potentiator or modulator molecules based on their
mechanism of action. Neisseria vaccines containing traditional adjuvants such as aluminium salts have existed
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review the use of natural, detoxified, or synthetic molecules in combination with antigens to activate the innate
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reacts with sialylated proteins in human tissues. Thus, outer
membrane vesicles (OMV) containing high amounts of surface
protein antigens from the pathogen have been used for
epidemic control e.g. in Cuba (2) and Norway (3). Despite the
OMV being strain-specific, some level of cross reaction has
been detected with the Cuban vaccine (Men B Finlay) (4)
Novel strategies using reverse vaccinology (5) and DNA
libraries constructed from bacterial genomes (6) have been
investigated in an attempt to predict universal antigens to
protect against B sero subtypes (7). However, these proteins,
peptides or plasmid DNA are also proving to be poorly
immunogenic and the traditional alum adjuvant is not
sufficient to induce appropriate levels of protection.  New
adjuvant strategies are therefore being devised based on a
combination of these antigens with immune potentiator,
molecules and/or delivery systems capable of efficiently
targeting immune response components such as dendritic
cells (DC).
Immune potentiator, modulator molecules and
delivery systems
The innate immune system utilizes multiple receptors (Pattern
Recognition Receptors, PRR) of fixed specificity to recognize
an enormously diverse array of ligands on microbes known
also as Pathogen-Associated Molecular Patterns (PAMPs)
(8). The most important PRR studied are the toll-like receptors
(TLR) which are transmembrane proteins that recognize
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PAMPs like: lipopolysaccharides (LPS, TLR4), lipopeptides
(TLR1 and 6), flagellin (TLR5) and nucleic acids (TLR7 or 8,
ssRNA; TLR9, unmethylated CpG) from pathogens. To date
13 TLR have been identified in mammals (9).
More than 60 million doses of the Cuban VA-MENGOC-BC®
Neisserial vaccine have been administered and it has shown
a good safety profile. It is composed of OMV which are nano
proteoliposome that contain important porin antigens (PorA
and PorB) and native LPS that stimulate DC through TLR4,
inducing IL-12 and γIFN cytokines characteristic of a Th1
pattern (10). One of the most important features of neisserial
proteoliposomes are their ability to deliver antigenic and
immune activating signals to DC (11).
Since LPS has also been described as toxic endotoxin, some
groups have worked on detoxified forms of it such as the 3-0-
desacyl-4'-monophosphoryl lipid A (MPL) that comes from LPS
of the Gram-negative Salmonella minnesota R595 or synthetic
LPS analogs such as RC529, which are less toxic than native
LPS. MPL and RC529 interact with TLR4 inducing a Th1
response similar to native LPS, but have failed to induce long
term memory of the stimulated CD4+ T cell subset (12). When
these structures have been encapsulated in poly(lactide-co-
glycolide) (PLG) microparticles an enhanced immune
response has been elicited against N. meningitidis B antigens
adsorbed on the microparticle surface (13).
MPL adsorbed onto alum is a GlaxoSmithKline Biologicals
(GSK) adjuvant used in humans, known as AS04 (14). It has
been used with several outer proteins from Neisseria and in
addition to the depot effect of alum, co-administered MPL
has been shown to redirect the classic Th2 pattern induced
by alum alone to a mixed Th1/Th2 response, which favours
the induction of protective immune responses. Emulsions
have also been formulated with Neisseria antigens, including:
MF59 a safe oil-in-water adjuvant used in humans (14) and
Titermax for experimental use only (15). Lucila et al. (15)
demonstrated that formulations using meningococcal C Ps
(PsC) conjugated to OMV from N. meningitidis B were very
efficient in inducing immune responses and long lasting
memory in a neonatal mice model. Co-encapsulation of Ps on
liposomes with immune potentiator or modulator molecules
such as CpG and CD40 is being studied as a non-covalent
alternative to conjugated Ps vaccines (16-17) and probably
offers a less expensive option to developing countries. OMV
have also been used to co-adjuvant the immune response to
plasmid DNA (6).
CpG is the ligand for TLR9 and activation leads to an enhanced
humoral and cell-mediated immune response through B-cell
stimulation to produce more immunoglobulin, as well as
promotion of a Th1 pattern and cytokine secretion by DC
(18). PLG anionic microparticles uploaded with CpG have
been described by Singh et al.(13) as a potent delivery system
for co-administered Neisseria meningitidis B recombinant
proteins and Malyala et al. (19) recently confirmed these
results.
Neisseria derivatives as vaccine adjuvants
Neisseria derivatives have been used to adjuvant many
antigens and advances in this field of study are perhaps as
important as the development of Neisseria vaccines
themselves. The Adjuvant Finlay PL 1 (AFPL1) is a Neisseria
derived PL that contains several PAMPs such as LPS, porins,
and DNA traces. Ovalbumin incorporated in AFPL1 is very
immunogenic when administered by the parenteral route, as
are allergen antigens co-adsorbed onto alum with the AFPL1;
inducing a Th1 response (20). Alternativly, the mucosally
administered Adjuvant Finlay Cochleate 1 (AFCo1) is a
microtubular structure derived from Neisseria PL interaction
with calcium (20). It is more stable and immunogenic than
AFPL1 and has also been used to adjuvant parenteral
administered antigens from Leishmania and malaria (21-22).
Intranasal immunization of AFCo1 with incorporated or co-
administered ovalbumin has been shown to induce strong
systemic and mucosal immune responses (20).
Protollin™ is the commercial name of a proprietary adjuvant
from ID Biomedical Corporation (subsequently GSK). This is
a non-covalent complex between Neisseria proteosomes and
Shigella flexneri 2ª LPS used mainly as a mucosal adjuvant.
Protollin™ is a safe formulation administered to humans
inducing mucosal and systemic immune responses against
Shigella (23) and has also been shown to protect mice from
respiratory syncytial virus (24).
Nasal route for Neisseria Vaccines
The respiratory tract is the site of entry and colonization of N.
meningitidis. In many cases non symptomatic individuals can
transmit the pathogen to others (25). Parenteral immunization
of the current Neisseria vaccines is effective in inducing
systemic immune responses, however to protect against
infection, the induction of immune responses at mucosal
surfaces is required (26). Conjugate Ps vaccines induce some
level of mucosal immune response and it has been suggested
that one of the most important successes of this vaccine relies
on the induction of herd immunity through mucosal stimulation
(27). Nevertheless, some formulations using liposomes
encapsulating serogroup C meningococcal Ps conjugated to
Escherichia coli heat labile enterotoxin mutant, LTK63 have
also been shown to induce potent mucosal and systemic
immune response when administered intranasally (28).
Similarly, when, the conjugated vaccine Menjugate C was
reformulated with chitosan, instead of alum, and intranasally
administered to humans, it showed similar systemic immune
responses and enhanced mucosal immune responses
compared with parenteral administration of the vaccine (29).
OMV from N. meningitidis B have also been used in clinical
trials; but the nasal immunization required 10 fold more
antigen per dose than the injectable form to induce similar
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systemic immune responses. However, these studies did not
evaluate mucosal immune responses (30). We too have found
that IN immunization with different OMV induce greater
mucosal immune responses than parenteral administration
(31). The IN route has also been used to test vaccine
candidates against N. gonorrhoea (32). Recombinant proteins
from this pathogen adjuvanted with cholera toxin subunit B
induced high immune responses at the genital tract, showing
that this route can also be used to stimulate distal mucosal
responses.
Commentary
Neisserial vaccine progression is very much related to
adjuvant development. Firstly, because Neisseria derivatives
are being used to adjuvant parenteral and mucosal vaccines
candidates from other microorganisms and secondly, novel
formulations based on combinations of delivery systems and
immune potentiator or modulator molecules are emerging to
face the global meningitis problem.
A “universal” B meningococcal vaccine strategy must be
accompanied by the selection of the right adjuvants, and
enables a number of adjuvant formulations to be examined
head-to-head. This would further remove the problem of
making the wrong choice of adjuvant or discarding good
candidates as a result of selecting a poor adjuvant
combination. Conjugated Ps vaccines have represented a
huge advance in protecting against Neisseria pathogens;
however they are too expensive, particularly for the
developing world. Current adjuvants could lead to the
improvement of new ways to formulate less expensive and
equally or more immunogenic antigens as an alternative to
conjugated Ps vaccines.
Development of better mucosal adjuvants is another approach
to obtain more effective vaccines against Neisseria, for the
induction of mucosal, as well as systemic immune response,
which could potentially protect vaccinees from the pathogen
and the population from pathogen spread. We predict that
over the next few years, this field will see a plethora of
combined current and novel adjuvant technologies directed
towards the mucosal route of administration.
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